Abeona Therapeutics INC 10-Q quarterly reports

Abeona Therapeutics Inc. reported its second quarter 2026 financial results, highlighting $11.4 million in product revenue from ZEVASKYN, while also disclosing ongoing operational losses and manufacturing hurdles.

Abeona Therapeutics Inc. reported its first quarter 2026 financial results, highlighting $8.7 million in product revenue from ZEVASKYN and a net loss of $17.1 million.

Abeona Therapeutics reported a significant net income for the nine months ended September 30, 2025, driven by the sale of its ZEVASKYN Priority Review Voucher, despite initial manufacturing challenges for its newly approved gene therapy.

Abeona Therapeutics reported a significant net income increase in Q2 2025, driven by the FDA approval of ZEVASKYN and the subsequent sale of its Priority Review Voucher for $155 million.

Abeona Therapeutics announces its Q1 2025 financial results, emphasizing the FDA approval of ZEVASKYN and the subsequent agreement to sell its Rare Pediatric Disease Priority Review Voucher for $155 million.

Abeona Therapeutics reported its financial results for the third quarter of 2024 and provided an update on the resubmission of its Biologics License Application (BLA) for pz-cel.

Abeona Therapeutics reported its second quarter 2024 financial results, highlighted by a net income of $7.4 million, and provided an update on the resubmission of its Biologics License Application (BLA) for pz-cel.

Abeona Therapeutics reported its first quarter 2024 financial results, highlighted by increased operating expenses and a net loss, while also facing a Complete Response Letter from the FDA regarding its pz-cel Biologics License Application.